Combination Therapy with Interferon-α2b, Ribavirin, and Amantadine in Chronic Hepatitis C Nonresponders to Interferon and Ribavirin

Abstract

Standard therapies for the treatment of hepatitis C are ineffective in almost 50% of patients. Amantadine is an antiviral agent that may have activity against hepatitis C virus. In this pilot study, we evaluated the efficacy of a combination of interferon, ribavirin, and amantadine in patients with chronic hepatitis C who had previously failed 6–12 months of treatment with interferon and ribavirin. In this prospective open-label study, 23 patients were treated with a combination of interferon-α2b 3 million units subcutaneously three times per week, ribavirin 1000–1200 mg daily, and amantadine 100 mg twice daily for 6–12 months. Treatment was discontinued at 6 months if the patients had detectable HCV RNA by PCR. All patients were followed for 6 months after the completion of treatment. At the end of treatment, the biochemical response was 47% and the virological response was 30%. However, the rate of sustained virological response was only 13% (3/23). There were no unexpected side effects with triple therapy. In conclusion, triple therapy with interferon, ribavirin and amantadine resulted in a low sustained viral clearance in chronic hepatitis C patients who had previously failed interferon and ribavirin combination therapy.

DOI: 10.1023/A:1022509304694

1 Figure or Table

Statistics

0200400600800'04'06'08'10'12'14'16
Citations per Year

798 Citations

Semantic Scholar estimates that this publication has 798 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Thuluvath2003CombinationTW, title={Combination Therapy with Interferon-α2b, Ribavirin, and Amantadine in Chronic Hepatitis C Nonresponders to Interferon and Ribavirin}, author={Paul J. Thuluvath and Hemant D. Pande and Joyce Maygers}, journal={Digestive Diseases and Sciences}, year={2003}, volume={48}, pages={594-597} }